Patients with unipolar, non-psychotic Major Depressive Disorder (MDD) receiving transcranial magnetic stimulation (TMS) with NeuroStar TMS Therapy® achieved significant improvement with their depressive symptoms and in their quality of life. NeuroStar TMS therapy positively impacted 58% of patients while 37% experienced remission.
“The improvements we observed show that non-drug therapy with NeuroStar TMS not only reduces the symptomatic suffering of patients, but lessens the disability of depression with important implications for these individuals’ ability to return to functioning effectively at home, in the workplace, and in the community,” explained Ian A. Cook, MD, Semel Institute for Neuroscience and Human Behavior at the University of California, Los Angeles.
TMS is a non-invasive, non-systemic therapeutic device that delivers magnetic resonance imaging (MRI) strength, pulsed, magnetic fields to create an electronic current in a targeted region of the brain: the cerebral cortex. The cerebral cortex is known to control mood. NeuroStar TMS Therapy is the first TMS therapy for MDD cleared by the FDA. It is the only TMS therapy proven to achieve remission without systemic side effects in patients who have not found relief with antidepressant medication.
Depression affects around 20 million Americans each year. About four million of those patients do not respond to standard treatments including drug and talk therapies despite repeated attempts with different combinations of therapies. Debilitating symptoms like anxiousness, sadness, irritability, chronic fatigue, changes in sleep patterns, loss of interest in enjoyable activities and digestive problems can be successfully treated for many people who try TMS Therapy.
Source: MedicalNewsToday, Tonic Life Communications